Sugi Predict

Sugi Predict / Compounds / SCHEMBL12465843

SCHEMBL12465843

SCHEMBL12465843

CN(C)/C=C/c1nc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ LMNA P02545 1/20 0.49
▸ MAP4K4 O95819 1/20 0.46
▸ CKS1B P61024 2/20 0.42
▸ SKP1 P63208 2/20 0.42
▸ SKP2 Q13309 2/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ MET P08581 1/20 0.41
▸ GPR119 Q8TDV5 6/20 0.40
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ MAPK1 P28482 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ SUV39H2 Q9H5I1 1/20 0.37
▸ PRKCQ Q04759 1/20 0.37
▸ PRMT5 O14744 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12465844 1.00 MAPT (0.49) MAPTALDH1A1LMNAMAP4K4CKS1B
SCHEMBL30772278 1.00 MAPT (0.49) MAPTALDH1A1LMNAMAP4K4CKS1B
SCHEMBL29318821 0.87 MAPT (0.54) MAPTALDH1A1LMNAMAP4K4CKS1B
SCHEMBL27930668 0.84 ALDH1A1 (0.37) MAPTALDH1A1LMNAGPR119MAPK1
SCHEMBL17461348 0.84 MAPT (0.40) MAPTALDH1A1MAPK1POLBTDP1
SCHEMBL28494337 0.83 MAP4K4 (0.39) MAPTALDH1A1LMNAMAP4K4PRKCQ
SCHEMBL16249710 0.81 GPR119 (0.45) MAPTALDH1A1LMNAGPR119
SCHEMBL23612029 0.81 MAPT (0.57) MAPTALDH1A1LMNAMAP4K4CKS1B
SCHEMBL3174381 0.81 MAPT (0.57) MAPTALDH1A1LMNAMAP4K4CKS1B
SCHEMBL30021896 0.81 MAPT (0.57) MAPTALDH1A1LMNAMAP4K4CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 — — US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 — — US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 — — US disclosed
WO-2024127297-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF PFIZER INC. (US) 2024-06-20 — — WO disclosed
CN-117561253-A Compounds and compositions for treating disorders related to STING activity 艾福姆德尤股份有限公司 2024-02-13 — — CN disclosed
CN-116942672-A Crystalline salts of B-RAF kinase inhibitors 徐诺药业公司 2023-10-27 — — CN disclosed
EP-4245758-A2 CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR Xynomic Pharmaceuticals, Inc. (US) 2023-09-20 — — EP disclosed
US-11753409-B2 Crystalline salts of a B-RAF kinase inhibitor XYNOMIC PHARMACEUTICALS, INC. (US) 2023-09-12 — — US disclosed
US-11753409-B2 Crystalline salts of a B-RAF kinase inhibitor XYNOMIC PHARMACEUTICALS, INC. (US) 2023-09-12 — — US disclosed
US-11753409-B2 Crystalline salts of a B-RAF kinase inhibitor XYNOMIC PHARMACEUTICALS, INC. (US) 2023-09-12 — — US disclosed
US-20200283433-A1 CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR XYNOMIC PHARMACEUTICALS, INC. 2020-09-10 — — US disclosed
US-20200283433-A1 CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR XYNOMIC PHARMACEUTICALS, INC. 2020-09-10 — — US disclosed
EP-2670749-B1 NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 — — EP disclosed
EP-2670749-B1 NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 — — EP disclosed
US-8889684-B2 Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 — — US disclosed
US-8889684-B2 Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 — — US disclosed
US-8889684-B2 Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 — — US disclosed
EP-2670749-A1 NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2013-12-11 — — EP disclosed
US-20130029993-A1 AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 — — US disclosed
WO-2012104388-A1 NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders HSD17B13, HSD17B3, HSD17B1 MAPT 2885/4885ALDH1A1 98/4885LMNA 1598/4885
US-20130029993-A1 AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS CDK2, CDKN1A, CDK1 MAPT 3633/4885ALDH1A1 2757/4885LMNA 3871/4885
US-20200283433-A1 CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR BRAF, RAF1, ARAF MAPT 2719/4885ALDH1A1 2930/4885LMNA 3492/4885
US-11753409-B2 Crystalline salts of a B-RAF kinase inhibitor BRAF, RAF1, ARAF MAPT 2719/4885ALDH1A1 2930/4885LMNA 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.